{"id":"triferic-avnu","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypophosphatemia"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Vascular access complications"}]},"_chembl":null,"_dailymed":{"setId":"51197a48-6078-42cd-b5ed-5ea22b6757b4","title":"TRIFERIC AVNU (FERRIC PYROPHOSPHATE CITRATE) SOLUTION [ROCKWELL MEDICAL INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Triferic AVNU (ferric pyrophosphate citrate) is administered intravenously during hemodialysis sessions and replaces iron lost during dialysis and due to chronic kidney disease-related blood loss. It works by providing bioavailable iron that is incorporated into hemoglobin and myoglobin, thereby correcting iron deficiency anemia in patients with chronic kidney disease on hemodialysis without requiring separate iron infusions.","oneSentence":"Triferic AVNU is an iron replacement therapy that delivers iron directly into the bloodstream during hemodialysis to treat iron deficiency anemia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:14:39.181Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Iron deficiency anemia in patients with chronic kidney disease on hemodialysis"}]},"trialDetails":[{"nctId":"NCT04689932","phase":"PHASE4","title":"Triferic AVNU Infusion Via Freedom Pump During Hemodialysis","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2021-04-19","conditions":"End Stage Renal Disease","enrollment":12},{"nctId":"NCT05110768","phase":"PHASE2","title":"Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy","status":"UNKNOWN","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2021-11-30","conditions":"Iron Deficiency Anemia","enrollment":75},{"nctId":"NCT04409132","phase":"PHASE1, PHASE2","title":"Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2020-06-25","conditions":"End Stage Renal Disease","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ferric Pyrophosphate Citrate (FPC)","FPC"],"phase":"marketed","status":"active","brandName":"Triferic AVNU","genericName":"Triferic AVNU","companyName":"Rockwell Medical Technologies, Inc.","companyId":"rockwell-medical-technologies-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triferic AVNU is an iron replacement therapy that delivers iron directly into the bloodstream during hemodialysis to treat iron deficiency anemia. Used for Iron deficiency anemia in patients with chronic kidney disease on hemodialysis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}